Ligation Methods for Peptide and Protein Synthesis with Applications to B-Peptide Assemblies*
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Amide-Forming Chemical Ligation Via O-Acyl Hydroxamic Acids
Amide-forming chemical ligation via O-acyl hydroxamic acids Daniel L. Dunkelmanna,1, Yuki Hirataa,1, Kyle A. Totaroa, Daniel T. Cohena, Chi Zhanga, Zachary P. Gatesa,2, and Bradley L. Pentelutea,2 aDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139 Edited by Jerrold Meinwald, Cornell University, Ithaca, NY, and approved February 28, 2018 (received for review October 20, 2017) The facile rearrangement of “S-acyl isopeptides” to native peptide ligation have relied on the use of thiol nucleophiles to form bonds via S,N-acyl shift is central to the success of native chemical S-acyl isopeptides, which undergo rapid S,N-acyl shifts through ligation, the widely used approach for protein total synthesis. small rings. An exception is the use of selenocysteine (23–26) α Proximity-driven amide bond formation via acyl transfer reactions and peptide- selenoesters (27, 28), which exhibit analogous but in other contexts has proven generally less effective. Here, we heightened reactivity. show that under neutral aqueous conditions, “O-acyl isopeptides” We sought to expand the scope of nucleophiles that might be derived from hydroxy-asparagine [aspartic acid-β-hydroxamic acid; employed in acyl transfer-based chemical ligation, and to rein- Asp(β-HA)] rearrange to form native peptide bonds via an O,N-acyl vestigate the possibility of O,N-acyl transfer across medium-size shift. This process constitutes a rare example of an O,N-acyl shift rings. Hydroxamic acids (29) were found to be sufficiently re- that proceeds rapidly across a medium-size ring (t1/2 ∼ 15 min), active to enable the formation of an O-acyl isopeptide from a α and takes place in water with minimal interference from hydroly- peptide- thioester and an N-terminal Asp(β-HA)-peptide at sis. -
Protein Ligation: an Enabling Technology for the Biophysical Analysis of Proteins Vasant Muralidharan & Tom W Muir
REVIEW Protein ligation: an enabling technology for the biophysical analysis of proteins methods Vasant Muralidharan & Tom W Muir Biophysical techniques such as fluorescence spectroscopy and nuclear magnetic .com/nature e resonance (NMR) spectroscopy provide a window into the inner workings of proteins. These approaches make use of probes that can either be naturally present within the .natur w protein or introduced through a labeling procedure. In general, the more control one has over the type, location and number of probes in a protein, then the more information one can extract from a given biophysical analysis. Recently, two related approaches have http://ww emerged that allow proteins to be labeled with a broad range of physical probes. Expressed oup r protein ligation (EPL) and protein trans-splicing (PTS) are both intein-based approaches G that permit the assembly of a protein from smaller synthetic and/or recombinant pieces. Here we provide some guidelines for the use of EPL and PTS, and highlight how the lishing b dovetailing of these new protein chemistry methods with standard biophysical techniques Pu has improved our ability to interrogate protein function, structure and folding. Nature 6 An intimate understanding of protein structure and studying protein structure and function in vitro. The goal 200 function remains a principal goal of molecular biology. of this review is to provide an overview of these protein- © The seemingly byzantine structure-activity relationships engineering approaches, with a particular eye toward the underlying protein function make this endeavor extreme- nonspecialist interested in using these techniques to gener- ly challenging and one that requires ever more sophistica- ate labeled proteins for biophysical studies. -
A Global Review on Short Peptides: Frontiers and Perspectives †
molecules Review A Global Review on Short Peptides: Frontiers and Perspectives † Vasso Apostolopoulos 1 , Joanna Bojarska 2,* , Tsun-Thai Chai 3 , Sherif Elnagdy 4 , Krzysztof Kaczmarek 5 , John Matsoukas 1,6,7, Roger New 8,9, Keykavous Parang 10 , Octavio Paredes Lopez 11 , Hamideh Parhiz 12, Conrad O. Perera 13, Monica Pickholz 14,15, Milan Remko 16, Michele Saviano 17, Mariusz Skwarczynski 18, Yefeng Tang 19, Wojciech M. Wolf 2,*, Taku Yoshiya 20 , Janusz Zabrocki 5, Piotr Zielenkiewicz 21,22 , Maha AlKhazindar 4 , Vanessa Barriga 1, Konstantinos Kelaidonis 6, Elham Mousavinezhad Sarasia 9 and Istvan Toth 18,23,24 1 Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia; [email protected] (V.A.); [email protected] (J.M.); [email protected] (V.B.) 2 Institute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego˙ 116, 90-924 Lodz, Poland 3 Department of Chemical Science, Faculty of Science, Universiti Tunku Abdul Rahman, Kampar 31900, Malaysia; [email protected] 4 Botany and Microbiology Department, Faculty of Science, Cairo University, Gamaa St., Giza 12613, Egypt; [email protected] (S.E.); [email protected] (M.A.) 5 Institute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego˙ 116, 90-924 Lodz, Poland; [email protected] (K.K.); [email protected] (J.Z.) 6 NewDrug, Patras Science Park, 26500 Patras, Greece; [email protected] 7 Department of Physiology and Pharmacology, -
(12) Patent Application Publication (10) Pub. No.: US 2011/0082079 A1 Spetzler Et Al
US 2011 0082079A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0082079 A1 Spetzler et al. (43) Pub. Date: Apr. 7, 2011 (54) GLUCAGON-LIKE PEPTDE-1 DERVATIVES Publication Classification AND THEIR PHARMACEUTICAL USE (51) Int. Cl. A638/22 (2006.01) (75) Inventors: Jane Spetzler, Bronsho (DK); C07K I4/575 (2006.01) Lauge Schäffer, Lyngby (DK); A6IP3/10 (2006.01) Jesper Lau, Farum (DK); Thomas A6IP 9/12 (2006.01) Kruse, Herlev (DK); Patrick A6IP3/04 (2006.01) William Garibay, Holte (DK); A6IP 9/10 (2006.01) Steffen Runge, Frederiksberg A6IPI/00 (2006.01) (DK); Henning Thogersen, Farum A6IPL/04 (2006.01) (DK); Ingrid Petersson, Frederiksberg (DK) (52) U.S. Cl. .......................... 514/7.2:530/399; 514/11.7 (57) ABSTRACT (73) Assignee: Novo Nordisk A/S, Bagsvard (DK) The invention relates to protracted Glucagon-Like Peptide-1 Appl. No.: (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 (21) 12/676,451 derivative of the invention comprises a modified GLP-1 (7- PCT Fled: 37) sequence having a total of 2-12 amino acid modifications, (22) Sep. 5, 2008 including Glu22 and Arg26, and being derivatised with an PCT NO.: PCT/EP2008/061755 albumin binding residue or pegylated in position 18, 20, 23. (86) 30, 31, 34, 36, 37, or 39. These compounds are useful in the S371 (c)(1), treatment or prevention of diabetes type 2 and related dis (2), (4) Date: Oct. 13, 2010 eases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of (30) Foreign Application Priority Data binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall Sep. -
Rapid Flow-Based Peptide Synthesis
Rapid Flow-Based Peptide Synthesis The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Simon, Mark D., Patrick L. Heider, Andrea Adamo, Alexander A. Vinogradov, Surin K. Mong, Xiyuan Li, Tatiana Berger, et al. “Rapid Flow-Based Peptide Synthesis.” ChemBioChem 15, no. 5 (March 11, 2014): 713–720. As Published http://dx.doi.org/10.1002/cbic.201300796 Publisher Wiley Blackwell Version Author's final manuscript Citable link http://hdl.handle.net/1721.1/96181 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ NIH Public Access Author Manuscript Chembiochem. Author manuscript; available in PMC 2015 March 21. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Chembiochem. 2014 March 21; 15(5): 713–720. doi:10.1002/cbic.201300796. Rapid Flow-Based Peptide Synthesis Mark D. Simona, Patrick L. Heiderb, Andrea Adamob, Alexander A. Vinogradova, Surin K. Monga, Xiyuan Lia, Tatiana Bergera, Rocco L. Policarpoa, Chi Zhanga, Yekui Zoua, Xiaoli Liaoa, Alexander M. Spokoynya, Prof Klavs F. Jensenb, and Prof Bradley L. Pentelutea Bradley L. Pentelute: [email protected] aDepartment of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, United States bDepartment of Chemical Engeneering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, United States Abstract A flow-based solid phase peptide synthesis methodology that enables the incorporation of an amino acid residue every 1.8 minutes under automatic control, or every three minutes under manual control, is described. -
Synthesis of Peptide and Protein Thioesters Through an N→S Acyl Shift
Native Chemical Thioesterification: Synthesis of Peptide and Protein Thioesters through an N→S Acyl Shift Jaskiranjit Kang A thesis submitted in partial fulfilment of the requirements for the degree award of: Doctor of Philosophy University College London Department of Chemistry 2010 Native Chemical Thioesterification: Synthesis of Peptide and Protein Thioesters through an N→S Acyl Shift Declaration I, Jaskiranjit Kang, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 Native Chemical Thioesterification: Synthesis of Peptide and Protein Thioesters through an N→S Acyl Shift Abstract The total chemical synthesis of a protein provides atomic-level control over its covalent structure, however polypeptides prepared by solid phase peptide synthesis are limited to approximately fifty amino acid residues. This limitation has been overcome by 'Native Chemical Ligation‘, which involves amide bond formation between two unprotected polypeptides: a peptide with a C-terminal thioester and an N-terminal cysteinyl peptide. Synthesis of the required peptide thioester is difficult, particularly by Fmoc-chemistry. During our studies towards the semisynthesis of erythropoietin, we discovered reaction conditions that reversed Native Chemical Ligation and generated peptide and protein thioesters through an N→S acyl transfer. O HS H3N O O O + H3O RSH N S SR H O A peptide with both a Gly-Cys and an Ala-Cys-Pro-glycolate ester sequence was selectively thioesterified between the Gly-Cys sequence upon microwave-heating at 80 °C with 30 % v/v 3-mercaptopropionic acid (MPA), to afford the peptide-Gly-MPA thioester (84 % yield). -
PYY(3-36) Analogues: Structure
PYY(3-36) analogues: Structure- activity relationships in energy homeostasis A thesis submitted for the degree of Doctor of Philosophy, Imperial College London 2011 Iain David Pritchard Section of Investigative Medicine Division of Diabetes, Endocrinology and Metabolism Department of Medicine Imperial College London Abstract The developed world is currently in the grip of an obesity epidemic. As a result, there is much ongoing research into the development of an effective anti-obesity agent. Peptide YY (PYY) is a 36 amino acid gastro-intestinal hormone released post- prandially by L-cells in the gastro-intestinal tract in proportion to the calorie content of a meal. The predominant form of the hormone found in circulation is the truncated PYY(3-36). Administration of PYY(3-36) at physiological doses to humans has been shown to reduce food intake. However, due to enzymatic degradation these effects are short lived, reducing the hormone’s utility as an anti-obesity pharmaceutical agent. A series of analogues of PYY(3-36) were designed either with amino acid substitutions in specific parts of the peptide sequence and/or with chemical modifications to the native sequence with the aim of increasing resistance to enzymatic activity whilst retaining or even enhancing the peptide’s bioactivity. The analogues were tested for resistance to degradation by different proteolytic enzymes in comparison to natural PYY(3-36). Their affinity to the Y2 receptor, for which PYY(3-36) is a natural agonist was then investigated. Finally, the effects of peripheral administration of selected analogues on food intake in overnight fasted mice were investigated. -
Peptides As Therapeutics with Enhanced Bioactivity
Send Orders of Reprints at [email protected] Current Medicinal Chemistry, 2012, 19, 4451-4461 4451 Peptides As Therapeutics with Enhanced Bioactivity D. Goodwin1, P. Simerska1 and I. Toth*,1,2, 1The University of Queensland, School of Chemistry and Molecular Biosciences; 2School of Pharmacy, St. Lucia 4072, Queensland, Australia Abstract: The development of techniques for efficient peptide production renewed interest in peptides as therapeutics. Numerous modi- fications for improving stability, transport and affinity profiles now exist. Several new adjuvant and carrier systems have also been developed, enhancing the immunogenicity of peptides thus allowing their development as vaccines. This review describes the established and experimental approaches for manufacturing peptide drugs and highlights the techniques currently used for improving their drug like properties. Keywords: Peptide, drug delivery, vaccine, manufacture, bioavailability, peptide therapeutic, immunogenicity, peptide drug, peptide synthe- sis, clinical trials. INTRODUCTION side-chain reactivity, degree of modification, incorporation of un- natural components, in addition to the required purity, solubility, Natural and synthetic peptides have shown promise as pharma- stability and scale. There are two strategies for peptide production - ceutics with the potential to treat a wide variety of diseases. This chemical synthesis and biological manufacturing. potential is often overshadowed by the inability of the peptides to reach their targets in an active form in vivo. The delivery of active Chemical Peptide Synthesis peptides is challenging due to inadequate absorption through the Chemical synthesis has been used for the production of peptides mucosa and rapid breakdown by proteolytic enzymes. Peptides are in both research and industry and led to the development of the usually selective and efficacious, therefore need only be present in majority of peptide drugs [2]. -
1 Peptide Therapeutics
Universal Free E-Book Store Donate Us, In order to keep our Service Alive, We have to pay for placing files (Abstracts, Books, Literature & Software) on File Hosting Servers, Your donations will make our process of payment a bit easier, Please use any one of the Payment Gateway for Donation. Never matter what amount you donate (10’s or 100’s or 1000’s). Universal Free E-Book Store Universal Free E-Book Store PEPTIDE CHEMISTRY AND DRUG DESIGN Universal Free E-Book Store Universal Free E-Book Store PEPTIDE CHEMISTRY AND DRUG DESIGN Edited by BEN M. DUNN Universal Free E-Book Store Copyright © 2015 by John Wiley & Sons, Inc. All rights reserved Published by John Wiley & Sons, Inc., Hoboken, New Jersey Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permissions. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. -
An Explorative Study Towards the Chemical Synthesis of the Immunoglobulin G1 Fc CH3 Domain
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Paris Lodron University of Salzburg Received: 10 June 2018 Revised: 26 August 2018 Accepted: 6 September 2018 DOI: 10.1002/psc.3126 RESEARCH ARTICLE An explorative study towards the chemical synthesis of the immunoglobulin G1 Fc CH3 domain Luigi Grassi1,2 | Cornelia Roschger2 | Vesna Stanojlović2 | Chiara Cabrele1,2 1 Christian Doppler Laboratory for Innovative Tools for Biosimilar Characterization, Monoclonal antibodies, fusion proteins including the immunoglobulin fragment c (Ig Fc) University of Salzburg, Hellbrunner Strasse 34, CH2‐CH3 domains, and engineered antibodies are prominent representatives of an 5020 Salzburg, Austria 2 Department of Biosciences, University of important class of drugs and drug candidates, which are referred to as biotherapeutics Salzburg, Billrothstrasse 11, 5020 Salzburg, or biopharmaceuticals. These recombinant proteins are highly heterogeneous due to Austria their glycosylation pattern. In addition, enzyme‐independent reactions, like Correspondence Chiara Cabrele, Department of Biosciences, deamidation, dehydration, and oxidation of sensitive side chains, may contribute to University of Salzburg, Billrothstrasse 11, their heterogeneity in a minor amount. To investigate the biological impact of a spon- 5020 Salzburg, Austria. Email: [email protected] taneous chemical modification, especially if found to be recurrent in a biotherapeutic, Funding information it would be necessary to reproduce it in a homogeneous manner. Herein, we undertook Austrian Federal Ministry of Science, an explorative study towards the chemical synthesis of the IgG1 Fc CH3 domain, which Research, and Economy; Land Salzburg; Start‐ up Grant of the State of Salzburg; University has been shown to undergo spontaneous changes like succinimide formation and of Salzburg methionine oxidation. -
The Investigation of Peptide and Protein-Glycosaminoglycan Binding
The Investigation of Peptide and Protein-Glycosaminoglycan Binding Interactions using Fluorescent Probes By Anthony F. Rullo A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Chemistry University of Toronto Copyright by Anthony F. Rullo 2012 Abstract The Investigation of Peptide and Protein-Glycosaminoglycan Binding Interactions using Fluorescent Probes Doctor of Philosophy Graduate Department of Chemistry University of Toronto Anthony F. Rullo 2012 The structural complexity of glycosaminoglycans (GAGs) such as heparin and heparan sulfate (HS) and their numerous biological roles, brings forth the need to develop new methods, capable of studying GAGs and their interactions with peptides and proteins under native settings. This thesis explores the development of chemical tools to study heparin/HS binding interactions under physiologically relevant conditions using fluorescence. In chapter 2, we designed peptide-based quinolinium probes to study the structural requirements of cationic peptides required for high affinity peptide-heparin interactions. These fluorescent probes enabled the study of peptide- heparin interactions at nM concentrations allowing the calculation of peptide-heparin binding constants. It was observed that peptides with positive charge displayed on one face of an α-helix in a continuous arrangement bound to heparin with the highest affinity and that heparin likely prefers to bind to these peptides while remaining in an extended conformation. In chapter 3, we set out to study an important biological role of HS which involves the binding and sequestering of proteins at the cell surface, facilitating endocytosis. HS has been implicated ii in the mechanism of cell penetrating peptide (CPP) cell uptake, with different CPPs showing different degrees of HS dependence on uptake as well as different mechanisms of entry. -
Application of the Logic of Cysteine-Free Native Chemical Ligation to the Synthesis of Human Parathyroid Hormone (Hpth)
Application of the logic of cysteine-free native chemical ligation to the synthesis of Human Parathyroid Hormone (hPTH) Shiying Shanga, Zhongping Tana, and Samuel J. Danishefskya,b,1 aBio-Organic Chemistry Laboratory, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065; and bDepartment of Chemistry, Columbia University, 3000 Broadway, New York, NY 10027 Contributed by Samuel J. Danishefsky, February 24, 2011 (sent for review December 13, 2010) The power of chemical synthesis of large cysteine-free polypep- stable forms of hPTH, where “pharmacolability” is attenuated tides has been significantly enhanced through the use of nonpro- without undercutting biological activity, would be of great inter- teogenic constructs which bear strategically placed thiol groups, est (26). It is also of interest to interrogate the consequences enabling native chemical ligation. Central to these much expanded of employing nonproteogenic inserts (27). While this goal can capabilities is the specific, radical-induced, metal-free dethiolation, be accomplished by cleverly designed recombinant methods, che- which can be accomplished in aqueous medium. mical synthesis could well be more convenient for servicing the initial production of probe structures for such structure-activity alanine ligation ∣ desulfurization ∣ leucine ligation ∣ peptide ∣ relationship (SAR) evaluations (28, 29). Previously, the chemical valine ligation synthesis of hPTH required either the solid phase synthesis of an 84-mer-long peptide or the assembly of fully protected peptide he chemical synthesis of proteins offers the potential of segments. Such methods are not ideal for the generation of ana- Tsolving a multitude of problems in biomedical sciences (1). logs (30–33).